Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jonathan Day, David Daly, Stephen Turner, More

Fluidigm: Jonathan Day
Fluidigm has appointed Jonathan Day as VP of commercial operations, Americas. Day was most recently VP of sales and support, Americas, for Agena Bioscience. Previously, he held roles of increasing responsibility at Thermo Fisher Scientific. Day also previously worked for Affymetrix.


Thrive: David Daly

Thrive has appointed David Daly as CEO and to its board of directors. Prior to Thrive, Daly served as senior VP and general manager of commercial operations at Illumina. Before Illumina, Daly served as general manager and chief commercial officer at Foundation Medicine. Prior to Foundation Medicine, Daly led the oncology business unit at Life Technologies, served as CCO at Clarient, and held roles at Roche Diagnostics and Abbott Laboratories.


Pacific Biosciences: Stephen Turner

Pacific Biosciences Chief Technology Officer Stephen Turner has become a senior research fellow at nematode screening firm NemaMetrix of Eugene, Oregon. Turner, a cofounder of PacBio, holds a PhD in physics from Cornell University and will maintain his current position at the firm.


For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.